Mana.bio
AI-driven drug delivery company that integrates machine learning with lipid nanoparticle (LNP) design and high-throughput wet-lab capabilities. Operates a closed-loop Design–Build–Test–Learn platform to design, synthesize, screen, and validate LNP formulations for delivery of nucleic acid therapeutics (RNA, DNA, oligonucleotides) with a focus on extrahepatic tissues (lung, T cells and other targets).
Industries
Nr. of Employees
small (1-50)
Products
Closed-loop LNP discovery platform
Platform that combines automated data ingestion, ML model training, in-silico design, high-throughput synthesis and screening to produce validated LNP delivery candidates.
Domain LLM and AI agent for nanoparticle formulation
A specialized language model and agent that assists with literature curation, property prediction and formulation suggestions specific to lipid nanoparticles.
AI-based
An AI platform designed to create targeted lipid nanoparticles to unlock nucleic acid delivery for therapeutic payloads like mRNA, CRISPR, and DNA.
Mana.bio AI-Driven LNP Delivery Platform
An AI platform designed to create targeted lipid nanoparticles to unlock nucleic acid delivery for therapeutic payloads like mRNA, CRISPR, and DNA.
Mana.bio AI LNP Platform
An AI-driven lipid nanoparticle platform designed to create targeted lipid nanoparticles for nucleic acid delivery.
Mana.bio AI-based LNP
AI-designed lipid-nanoparticles engineered to deliver genetic payloads like RNA to specific cells within the body.
Closed-loop LNP discovery platform
Platform that combines automated data ingestion, ML model training, in-silico design, high-throughput synthesis and screening to produce validated LNP delivery candidates.
Domain LLM and AI agent for nanoparticle formulation
A specialized language model and agent that assists with literature curation, property prediction and formulation suggestions specific to lipid nanoparticles.
AI-based
An AI platform designed to create targeted lipid nanoparticles to unlock nucleic acid delivery for therapeutic payloads like mRNA, CRISPR, and DNA.
Mana.bio AI-Driven LNP Delivery Platform
An AI platform designed to create targeted lipid nanoparticles to unlock nucleic acid delivery for therapeutic payloads like mRNA, CRISPR, and DNA.
Mana.bio AI LNP Platform
An AI-driven lipid nanoparticle platform designed to create targeted lipid nanoparticles for nucleic acid delivery.
Mana.bio AI-based LNP
AI-designed lipid-nanoparticles engineered to deliver genetic payloads like RNA to specific cells within the body.
Services
A wet-lab-connected platform that digests public and proprietary data, trains models, designs novel lipids and formulations, synthesizes candidates and tests them in vitro and in vivo.
A publicly accessible AI agent that provides curated literature, predictive property estimates and formulation optimization guidance for LNP research.
A wet-lab-connected platform that digests public and proprietary data, trains models, designs novel lipids and formulations, synthesizes candidates and tests them in vitro and in vivo.
A publicly accessible AI agent that provides curated literature, predictive property estimates and formulation optimization guidance for LNP research.
Expertise Areas
- Lipid nanoparticle design and formulation
- Machine learning for drug delivery
- High-throughput formulation synthesis and screening
- Preclinical in-vivo validation (including NHP)
Key Technologies
- Machine learning and predictive modeling
- Domain-specific large language model (LLM) for LNPs
- High-throughput automated synthesis
- Automated high-throughput screening assays
News & Updates
Launch of a domain-specific large-language-model agent that provides curated data, predictive modeling and formulation guidance for LNP research.
Three poster presentations demonstrating ML-driven LNP design for T-cell and lung delivery and improvements in potency and safety.
Joined a technology network to integrate delivery capabilities and collaborate with partner R&D resources.
Collaboration with a clinical research center to apply AI-driven LNP technology to cancer and autoimmune disease RNA therapies.
Closed a $19.5M seed financing round to advance the AI-based LNP platform for nucleic acid therapeutics.
Reported preclinical improvements in systemic LNP tolerability including reduced cytokine responses and improved tolerable dosing.
Launch of a domain-specific large-language-model agent that provides curated data, predictive modeling and formulation guidance for LNP research.
Three poster presentations demonstrating ML-driven LNP design for T-cell and lung delivery and improvements in potency and safety.
Joined a technology network to integrate delivery capabilities and collaborate with partner R&D resources.
Collaboration with a clinical research center to apply AI-driven LNP technology to cancer and autoimmune disease RNA therapies.
Closed a $19.5M seed financing round to advance the AI-based LNP platform for nucleic acid therapeutics.
Reported preclinical improvements in systemic LNP tolerability including reduced cytokine responses and improved tolerable dosing.